Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (54 quarters reported)
$754M in Q2 2013 → $9.97B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ascendis Pharma A/s | 23.5% | Unchanged | 10,281,496 | $2.34B |
| PM Parabilis Medicines Inc | 9.5% | Added 0.8% | 29,177,964 | $942M |
| Vaxcyte Inc | 6.5% | Unchanged | 11,474,599 | $653M |
| Rhythm Pharmaceuticals Inc | 6.4% | Unchanged | 6,666,837 | $635M |
| Edgewise Therapeutics Inc | 3.4% | Unchanged | 8,392,730 | $341M |
| Tyra Biosciences Inc | 2.7% | Unchanged | 12,198,625 | $267M |
| Freenome Inc | 2.4% | New | 15,367,270 | $242M |
| Hemab Therapeutics Holdings | 2.4% | Unchanged | 7,808,627 | $241M |
| NP Newamsterdam Pharma Co Nv | 2.3% | Unchanged | 9,550,191 | $232M |
| Septerna Inc | 2.2% | Trimmed 21% | 5,502,858 | $215M |
| Spyglass Pharma Inc | 2.1% | Unchanged | 8,021,117 | $209M |
| Janux Therapeutics Inc | 1.9% | Unchanged | 11,189,693 | $193M |
| Mineralys Therapeutics Inc | 1.9% | Unchanged | 7,692,750 | $193M |
| Disc Medicine Inc | 1.6% | Unchanged | 2,450,221 | $160M |
| Taysha Gene Therapies Inc | 1.5% | Added 29% | 30,435,190 | $148M |
| Bicara Therapeutics Inc | 1.4% | Unchanged | 7,255,993 | $135M |
| Artiva Biotherapeutics Inc | 1.3% | Added 3.0% | 18,489,293 | $132M |
| Xencor Inc | 1.3% | Unchanged | 5,274,274 | $132M |
| Oruka Therapeutics Inc | 1.3% | Unchanged | 1,554,597 | $129M |
| Amylyx Pharmaceuticals Inc | 1.2% | New | 4,279,341 | $125M |
| Climb Bio Inc | 1.2% | Trimmed 10% | 10,130,130 | $116M |
| AS Abivax Sa-adr | 1.0% | Trimmed 9.1% | 1,030,058 | $102M |
| Wave Life Sciences Inc | 1.0% | New | 26,975,505 | $99.8M |
| LB Latigo Biotherapeutics Inc | 0.9% | New | 5,302,933 | $88.6M |
| Solid Biosciences Inc | 0.9% | Unchanged | 12,036,126 | $87M |
| Vor Biopharma Inc | 0.9% | Added 87% | 4,503,882 | $85.9M |
| Lb Pharmaceuticals Inc | 0.9% | Unchanged | 2,208,604 | $84.8M |
| Gh Research PLC | 0.8% | Trimmed 53% | 3,609,007 | $84.7M |
| Obsidian Therapeutics Inc | 0.8% | New | 5,957,103 | $81.8M |
| ZL Zai Lab Ltd-adr | 0.7% | Trimmed 51% | 2,815,543 | $74.2M |
| 4M 4d Molecular Therapeutics In | 0.7% | Unchanged | 5,049,779 | $72.3M |
| Aclaris Therapeutics Inc | 0.7% | Unchanged | 12,723,026 | $66.9M |
| Sana Biotechnology Inc | 0.5% | Unchanged | 18,750,000 | $54.7M |
| Monopar Therapeutics Inc | 0.5% | Unchanged | 667,207 | $53.2M |
| Geron Corp | 0.5% | Trimmed 0.1% | 42,754,145 | $52.6M |
| Damora Therapeutics Inc | 0.5% | New | 2,399,702 | $51.1M |
| Pepgen Inc | 0.5% | Unchanged | 20,064,545 | $48.6M |
| Ars Pharmaceuticals Inc | 0.5% | Unchanged | 10,860,977 | $46.8M |
| Acumen Pharmaceuticals Inc | 0.5% | Unchanged | 20,992,669 | $46.6M |
| DT Dbv Technologies Sa-spon ADR | 0.4% | New | 3,657,644 | $43M |
| Agenus Inc | 0.4% | New | 4,122,000 | $40.9M |
| Rezolute Inc | 0.4% | Unchanged | 9,445,039 | $39.1M |
| Sionna Therapeutics Inc | 0.3% | Trimmed 35% | 6,456,234 | $34M |
| ST Scribe Therapeutics Inc | 0.3% | New | 1,802,178 | $33.2M |
| Century Therapeutics Inc | 0.3% | Unchanged | 17,754,430 | $30.4M |
| Evommune Inc | 0.3% | Unchanged | 3,494,638 | $28.9M |
| Korsana Biosciences Inc | 0.3% | New | 892,743 | $28.6M |
| Capricor Therapeutics Inc | 0.3% | Added 100% | 3,014,183 | $28.5M |
| Nkarta Inc | 0.3% | Unchanged | 10,805,129 | $28.3M |
| C4 Therapeutics Inc | 0.3% | Added 2.4% | 8,194,779 | $27.3M |
| Jade Biosciences Inc | 0.3% | Trimmed 50% | 1,835,542 | $25.8M |
| Prelude Therapeutics Inc | 0.3% | Unchanged | 6,475,882 | $25.3M |
| Acrivon Therapeutics Inc | 0.3% | Unchanged | 12,229,396 | $25.1M |
| Assembly Biosciences Inc | 0.2% | Unchanged | 1,020,410 | $24M |
| Editas Medicine Inc | 0.2% | Unchanged | 8,889,000 | $22.8M |
| Q32 Bio Inc | 0.2% | Unchanged | 2,332,457 | $19.3M |
| Anteris Technologies Global | 0.2% | Trimmed 18% | 2,474,076 | $19.2M |
| ET Electra Therapeutics Inc | 0.2% | New | 1,692,965 | $19M |
| Altimmune Inc | 0.2% | Unchanged | 6,500,000 | $18.6M |
| Benitec Biopharma Inc | 0.2% | Unchanged | 1,850,000 | $18.5M |
Showing top 60 of 92 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Freenome Inc | New | +15,367,270 | +$242M | 2.4% |
| Biocryst Pharmaceuticals Inc | Exited | −15,827,186 | −$158M | — |
| Wave Life Sciences Ltd | Exited | −26,975,505 | −$157M | — |
| NI Nuvalent Inc-a | Exited | −1,246,456 | −$154M | — |
| Amylyx Pharmaceuticals Inc | New | +4,279,341 | +$125M | 1.2% |
| Wave Life Sciences Inc | New | +26,975,505 | +$99.8M | 1.0% |
| Gh Research PLC | Trimmed | −4,027,806 | −$94.6M | 0.8% |
| LB Latigo Biotherapeutics Inc | New | +5,302,933 | +$88.6M | 0.9% |
| Obsidian Therapeutics Inc | New | +5,957,103 | +$81.8M | 0.8% |
| ZL Zai Lab Ltd-adr | Trimmed | −2,927,990 | −$77.1M | 0.7% |
Showing the 10 largest of 53 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ascendis Pharma A/s | New | +10,281,496 | +$2.74B | 23.8% |
| AP Ascendis Pharma A/s - ADR | Exited | −10,281,496 | −$2.35B | — |
| PM Parabilis Medicines Inc | New | +28,933,371 | +$792M | 6.9% |
| Hemab Therapeutics Holdings | New | +7,808,627 | +$287M | 2.5% |
| Dianthus Therapeutics Inc | Exited | −2,611,733 | −$219M | — |
| NI Nuvalent Inc-a | Trimmed | −1,287,689 | −$159M | 1.3% |
| AS Abivax Sa-adr | New | +1,132,557 | +$151M | 1.3% |
| Oruka Therapeutics Inc | New | +1,554,597 | +$148M | 1.3% |
| PP Praxis Precision Medicines I | Exited | −373,787 | −$120M | — |
| Sarepta Therapeutics Inc | Exited | −3,902,596 | −$84.9M | — |
Showing the 10 largest of 55 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cidara Therapeutics Inc | Exited | −3,365,523 | −$743M | — |
| Avidity Biosciences Inc | Exited | −8,641,031 | −$623M | — |
| Spyglass Pharma Inc | New | +8,021,117 | +$208M | 2.2% |
| ZL Zai Lab Ltd-adr | New | +5,707,262 | +$107M | 1.1% |
| Sarepta Therapeutics Inc | New | +3,902,596 | +$84.9M | 0.9% |
| Dianthus Therapeutics Inc | Added | +1,000,000 | +$83.9M | 2.3% |
| Arcellx Inc | Exited | −1,267,156 | −$82.6M | — |
| BB Belite Bio Inc - ADR | Exited | −432,484 | −$69.2M | — |
| NI Nuvalent Inc-a | Added | +654,088 | +$67M | 2.8% |
| Wave Life Sciences Ltd | Added | +8,772,496 | +$63.6M | 2.1% |
Showing the 10 largest of 53 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 89bio Inc | Exited | −19,889,683 | −$292M | — |
| Climb Bio Inc | Trimmed | −20,125,439 | −$138M | 0.8% |
| Biocryst Pharmaceuticals Inc | New | +15,827,186 | +$123M | 1.3% |
| Arcellx Inc | Trimmed | −1,769,371 | −$115M | 0.8% |
| PP Praxis Precision Medicines I | New | +373,787 | +$110M | 1.1% |
| Rhythm Pharmaceuticals Inc | Added | +985,478 | +$105M | 7.3% |
| BB Belite Bio Inc - ADR | Trimmed | −442,516 | −$70.8M | 0.7% |
| Olema Pharmaceuticals Inc | New | +2,600,000 | +$65M | 0.7% |
| NI Nuvalent Inc-a | Added | +633,601 | +$63.7M | 1.9% |
| Evommune Inc | New | +3,458,770 | +$59.2M | 0.6% |
Showing the 10 largest of 61 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| NI Nuvalent Inc-a | New | +1,246,456 | +$108M | 1.3% |
| Vor Biopharma Inc | New | +1,982,301 | +$96.6M | 1.2% |
| Dyne Therapeutics Inc | Exited | −9,714,392 | −$92.5M | — |
| BB Belite Bio Inc - ADR | New | +875,000 | +$64.8M | 0.8% |
| Vor Biopharma Inc | Exited | −39,646,039 | −$64.2M | — |
| Avidity Biosciences Inc | Added | +1,375,000 | +$59.9M | 4.6% |
| Rxsight Inc | Exited | −3,702,967 | −$48.1M | — |
| Mineralys Therapeutics Inc | Added | +1,176,470 | +$44.6M | 3.4% |
| Pepgen Inc | Added | +9,375,000 | +$43.3M | 1.1% |
| Tourmaline Bio Inc | Exited | −2,538,925 | −$40.6M | — |
Showing the 10 largest of 36 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cidara Therapeutics Inc | Added | +2,272,727 | +$111M | 2.8% |
| Apogee Therapeutics Inc | Exited | −1,569,491 | −$58.6M | — |
| ZL Zai Lab Ltd-adr | Exited | −1,295,040 | −$46.8M | — |
| DO Day One Biopharmaceuticals I | Exited | −5,755,577 | −$45.6M | — |
| Urogen Pharma Ltd | Exited | −3,206,271 | −$35.5M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −523,053 | −$33.1M | 5.9% |
| Taysha Gene Therapies Inc | Added | +12,683,145 | +$29.3M | 0.9% |
| Avidity Biosciences Inc | Added | +965,623 | +$27.4M | 3.5% |
| Astria Therapeutics Inc | Exited | −5,105,213 | −$27.3M | — |
| Kura Oncology Inc | Exited | −4,004,610 | −$26.4M | — |
Showing the 10 largest of 52 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LB Legend Biotech Corp-adr | Exited | −7,506,934 | −$244M | — |
| Vaxcyte Inc | Added | +3,499,959 | +$132M | 7.7% |
| SS SPDR S&P Biotech ETF | Exited | −1,228,240 | −$111M | — |
| Sionna Therapeutics Inc | New | +10,445,322 | +$109M | 1.8% |
| Axsome Therapeutics Inc | Exited | −1,000,000 | −$84.6M | — |
| VP Verona Pharma PLC - ADR | Exited | −1,766,830 | −$82.1M | — |
| Disc Medicine Inc | New | +1,577,106 | +$78.3M | 1.3% |
| PP Praxis Precision Medicines I | Exited | −761,955 | −$58.6M | — |
| RP Recursion Pharmaceuticals-a | Exited | −7,725,096 | −$52.2M | — |
| Geron Corp | Added | +30,369,830 | +$48.3M | 1.6% |
Showing the 10 largest of 44 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biogen Inc | Exited | −1,184,456 | −$230M | — |
| Septerna Inc | New | +6,995,858 | +$160M | 2.1% |
| VP Verona Pharma PLC - ADR | Trimmed | −3,242,823 | −$151M | 1.1% |
| SS SPDR S&P Biotech ETF | New | +1,228,240 | +$111M | 1.5% |
| Arcellx Inc | Added | +935,848 | +$71.8M | 2.8% |
| Janux Therapeutics Inc | Added | +1,200,000 | +$64.2M | 7.4% |
| EH Evolent Health Inc - A | Trimmed | −4,937,665 | −$55.5M | 0.5% |
| AP Ascendis Pharma A/s - ADR | Added | +402,316 | +$55.4M | 18.5% |
| Cg Oncology Inc | Exited | −1,397,433 | −$52.7M | — |
| RP Recursion Pharmaceuticals-a | Trimmed | −7,659,519 | −$51.8M | 0.7% |
Showing the 10 largest of 51 changes.
Loading...